AU6028399A - Canine milk substitute - Google Patents
Canine milk substitute Download PDFInfo
- Publication number
- AU6028399A AU6028399A AU60283/99A AU6028399A AU6028399A AU 6028399 A AU6028399 A AU 6028399A AU 60283/99 A AU60283/99 A AU 60283/99A AU 6028399 A AU6028399 A AU 6028399A AU 6028399 A AU6028399 A AU 6028399A
- Authority
- AU
- Australia
- Prior art keywords
- composition
- milk
- acid
- weight
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282465 Canis Species 0.000 title claims description 21
- 235000013384 milk substitute Nutrition 0.000 title claims description 12
- 239000000203 mixture Substances 0.000 claims description 71
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000000194 fatty acid Substances 0.000 claims description 25
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 23
- 150000004665 fatty acids Chemical class 0.000 claims description 23
- 235000019197 fats Nutrition 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 14
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 11
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 11
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 11
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 235000020776 essential amino acid Nutrition 0.000 claims description 10
- 239000003797 essential amino acid Substances 0.000 claims description 10
- 239000005862 Whey Substances 0.000 claims description 9
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 9
- 239000005018 casein Substances 0.000 claims description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 8
- 235000021240 caseins Nutrition 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 235000021342 arachidonic acid Nutrition 0.000 claims description 7
- 229940114079 arachidonic acid Drugs 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 235000014121 butter Nutrition 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000002285 corn oil Substances 0.000 claims description 4
- 235000005687 corn oil Nutrition 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229940060184 oil ingredients Drugs 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
- 239000006014 omega-3 oil Substances 0.000 claims description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 3
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 2
- 239000008267 milk Substances 0.000 description 70
- 235000013336 milk Nutrition 0.000 description 69
- 210000004080 milk Anatomy 0.000 description 69
- 239000003925 fat Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000006651 lactation Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000011632 Caseins Human genes 0.000 description 8
- 108010076119 Caseins Proteins 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 230000000474 nursing effect Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035611 feeding Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000361 cobalt sulfate Inorganic materials 0.000 description 2
- 229940044175 cobalt sulfate Drugs 0.000 description 2
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- 229960000355 copper sulfate Drugs 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- -1 niacinaminde Chemical compound 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229960002816 potassium chloride Drugs 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 229960004839 potassium iodide Drugs 0.000 description 2
- 235000007715 potassium iodide Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QACUPNAKIPYZAW-RMQWDSPGSA-N O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QACUPNAKIPYZAW-RMQWDSPGSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000008212 improved nutritional status Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/04—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk fats but no non-milk proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/802—Simulated animal flesh
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/805—Pet food for dog, cat, bird, or fish
Description
WO 00/18247 PCT/US99/20469 CANINE MILK SUBSTITUTE This invention relates to a canine milk substitute, or bitch milk replacer, which substantially supplies the nutritional requirements of nursing puppies and critical care canines. 5 In recent years, the nutritional requirements of growing puppies as well as adult dogs have been studied; however, little information has been acquired on the composition of canine milk and how it meets the nutritional requirements of nursing puppies. It is generally accepted that milk from the lactating mother provides optimal nutrition to the suckling puppy. Accordingly, milk replacers currently in use have 10 been formulated with the intent of matching the nutrient composition of bitch milk. However, most of the commercially known formulations are based on studies conducted with regard only to crude protein, fat and mineral concentrations in the milk of lactating mothers. See Lonnerdal et al., "Developmental Changes in the Composition of Beagle Dog Milk", Am. J. Vet. Res., Vol. 42:662-666 (1981) and 15 Oftedal, "Lactation in the Dog: Milk Composition and Intake by Puppies", J. Nutr., 114:803-812 (1984). Little study has been devoted to important information such as fatty acid and amino acid profiles in bitch milk and other factors which are believed to have an effect on the nutrient profiles of bitch milk including breed and stage of lactation. 20 Accordingly, as currently available commercial bitch milk replacers have been formulated based on limited research data, they do not necessarily provide adequate nutrition to the nursing puppy to ensure proper development and growth. Therefore, there is still a need in the art for a canine milk replacer which is based more closely on the actual concentrations of essential nutrients in bitch milk and which 25 substantially supplies the nutritional needs of nursing puppies. The present invention meets that need by providing a canine milk substitute, or milk replacer, containing amounts of protein, fat and carbohydrates which closely matches the concentrations of those components in bitch milk. In addition, the milk replacer of the present invention provides improved fatty acid and amino acid profiles WO 00/18247 PCT/US99/20469 -2 over currently available bitch milk replacers, and has been found to enhance growth in nursing puppies as compared to currently available commercial products. The milk replacer also provides a high quality, highly digestible nutrient source for critical care canines. 5 In accordance with one aspect of the present invention, an artificially produced canine milk substitute composition is provided which comprises, on a dry matter basis (DMB), from about 35 to 45% by weight protein, from about 25 to 35% by weight fat, and from about 10 to 25% by weight carbohydrates. In a preferred embodiment of the invention, the composition comprises about 38% protein, about 28% fat, and 10 about 19% carbohydrates. The protein source preferably comprises casein and whey in a weight ratio of about 70:30. The source of fat is preferably selected from the group consisting of corn oil, canola oil, butter oil, arachidonic acid, docosahexaenoic acid and blends thereof. 15 The composition of the present invention also preferably contains fatty acids comprising, as a percentage of total fatty acids on a dry matter basis, from about 15 to 19% palmitic acid, from about 5 to 9% stearic acid, from about 34 to 38% oleic acid, from about 17 to 21% linoleic acid, from about 1 to 4% a-linolenic acid, from about 0.5 to 2% arachidonic acid, from about 0.2 to 1.0% docosahexaenoic acid 20 (DHA), from about 2 to 5% Omega 3 fatty acids, from about 18 to 22% Omega 6 fatty acids, and from about 1 to 4% trans fatty acids. The composition preferably contains 27 to 37% by weight fatty acids on a dry matter basis. The composition also contains essential amino acids comprising, as a percentage of total essential amino acids on a dry matter basis, from about 6 to 10% 25 arginine, 4 to 8% histidine, 8 to 12% isoleucine, 16 to 20% leucine, from about 13 to 17% lysine, from about 2 to 7% methionine, from about 6 to 10% phenylalanine, from about 8 to 12% threonine, from about 1 to 4% tryptophan, from about 9 to 13% valine, from about 2 to 5% cystine, and from about 2 to 6% tyrosine. The composition preferably contains from about 15 to 25% by weight essential amino 30 acids on a dry matter basis.
WO 00/18247 PCT/US99/20469 -3 The composition also preferably contains, on a dry matter basis, from about 4 to 8% by weight lactose and from about 0.50% by weight fructooligosaccharide. The composition may also include mixtures of vitamins and minerals. When the composition of the present invention is fed to puppies in a quantity 5 and frequency appropriate for their nutritional needs, it has been found that the puppies exhibit exceptional growth performance which is superior to other currently available canine milk replacers and which is very similar in pattern to maternally reared puppies. Accordingly, it is a feature of the present invention to provide a canine milk 10 substitute that duplicates canine milk more closely than currently available products and which substantially supplies the nutrient requirements of nursing puppies and critical care canines. Other features and advantages of the invention will be apparent from the following description, the accompanying drawings, and the appended claims. 15 In order that the invention may be more readily understood, reference will now be made by example to the accompanying drawings, in which: Fig. 1 is a bar graph showing percentages of protein, fat and carbohydrates in the composition of the present invention compared with those contained in commercially available bitch milk replacers and bitch milk; Fig. 2 is a bar graph 20 showing the fatty acid profile of the composition of the present invention compared with the profiles of commercially available bitch milk replacers and bitch milk; and Fig. 3 is a bar graph showing the amino acid profile of the composition of the present invention compared with the profiles of commercially available bitch milk replacers and bitch milk. 25 The milk substitute composition of the present invention provides an improvement over currently available milk substitutes in that it more closely matches the nutrient profile of bitch milk. The composition of the present invention is higher in protein and lower in fat content that currently commercially available milk replacers. For example, the composition of the present invention preferably comprises at least 30 38% by weight protein in comparison to currently available milk replacers which WO 00/18247 PCT/US99/20469 -4 comprise only about 29 to 34% protein. In addition, the composition of the present invention comprises only about 28% by weight fat in comparison to currently available milk replacers which comprise from about 33 to 42% fat. The present invention also provides amino acid profiles and fatty acid profiles 5 which are closer to that of bitch milk than commercially available products. When the milk replacer composition of the present invention is fed to puppies on a daily basis, it has been found to provide greater daily weight gain and improved growth performance than commercially available milk replacer products. The composition is preferably provided in powder form, but may be provided in 10 any suitable form (e.g., liquid) as long as it contains the preferred concentrations of protein, fat, and carbohydrates on a dry matter basis. While the milk replacer of the present invention has been described primarily for administration to puppies, it should also be appreciated that the milk replacer may be administered to critical care canines. By "critical care canines", it is meant those 15 animals which are under extreme stress due to, for example, extensive trauma, systemic disease, cancer, chemotherapy, malnutrition, ingestion of toxins, or postoperative trauma. Such conditions cause the critical care animal to have higher energy requirements than healthy animals. The canine milk substitute is suitable for use as a critical care diet as it provides high quality, highly digestible nutrient sources. 20 In addition, the canine milk substitute may be provided in liquid form for tube feeding and is highly palatable so as to encourage voluntary intake. A study of bitch milk was undertaken to determine the concentration of true protein, total fat, total carbohydrates, the casein to whey ratio, the amino acid profile, and the fatty acid profile. The testing procedures and results are described below. 25 Milk samples (approximately 10 mL) were collected from a total of 10 beagle dogs on days 1, 3, 7, 14, 21, 28, 35 and 42 of lactation and stored frozen until subjected to laboratory analysis. All bitches were maintained on the same diet. Bitch and individual puppy body weights were recorded on the days of milk collection. Nitrogen analysis--Total nitrogen, NPN, and true protein nitrogen were 30 analyzed by micro-Kjeldahl.
WO 00/18247 PCT/US99/20469 -5 Casein:whey ratio--The casein to whey ratio was determined by gel electrophoresis following the determination of the optimal separation conditions for these two class of proteins. Amino Acids--Amino acid profiles were determined for milk and for the whey 5 and casein proteins. Fatty Acids--Fatty acids profiles were analyzed by gas chromatography. Lactose--Lactose was determined by the lactase assay and total lipids via the Folch procedure. Minerals--Mineral composition was determined by atomic absorption 10 spectrometry. Milk proteins--Milk protein composition was determined by gel electrophoresis and by FPLC using gel filtration and ion-exchange chromatography. Isolated proteins were identified by N-terminal sequencing. Results 15 Protein concentration was very high in day 1 samples (144 ± 60 g/L), then decreased through day 21 (68 ± 13 g/L); a modest increase was then observed. There was no change in the concentration of NPN (approximately 6-10% of total N). The casein/whey ratio was about 70/30 and stayed constant throughout lactation. Lactose concentration increased during early lactation: day 1 samples contained 17 20 4 g/L, while day 7 to day 42 samples contained 34-40 g/L. Lipid concentration was high in early lactation(approximately 13%) and then decreased slightly (approximately 11%). Citrate concentration increased from day 1 to day 7 (4.8 ± 1.2 to 6.6 ± 1.0 mM), then gradually decreased by day 42 (3.9 ± 1.2 mM). Although data was developed through the duration of lactation, only the data 25 for day 7 of lactation are described below. Because milk composition changes throughout the course of lactation and the nutrient needs of puppies are most critical during the first two weeks of life, it was determined that this early milk composition was the most appropriate data upon which to base a single milk replacer formulation. All of the following data are presented on a dry matter basis. The percentages in the WO 00/18247 PCT/US99/20469 -6 essential amino acid and fatty acid profiles are expressed as a percentage of total essential amino acids and total fatty acids, respectively. Composition Protein 40.40% 5 Fat 31.8%* Carbohydrate 18.5% Casein/Whey Ratio 70:30 Essential Amino Acid Profile (%) Arginine 9.70 10 Histidine 6.37 Isoleucine 8.94 Leucine 22.14 Lysine 8.92 Methionine 5.40 15 Cystine 3.84 Phenylalanine 7.83 Tyrosine 5.61 Threonine 8.25 Tryptophan 1.06 20 Valine 11.9 *This value was obtained from Lonnerdal et al., "Developmental Changes in the Composition of Beagle Dog Milk", Am. J. Vet. Res., Vol. 42:662-666 (1981) and Oftedal, "Lactation in the Dog: Milk Composition and Intake by Puppies", J. Nutr., 25 114:803-812 (1984).
WO 00/18247 PCT/US99/20469 -7 Fatty Acid Profile (%) Palmitic 24.30 Stearic 2.90 Oleic 36.5 5 Linoleic 14.5 Arachidonic 1.22 Docosahexaenoic 0.70 Trans Fatty acids 3.40 Based on this data, the bitch milk replacer of the present invention was 10 formulated and preferably contains about 38% protein, about 28% fat, and about 19% carbohydrates. The casein and whey in the composition have a weight ratio of about 70:30. The source of fat in the milk replacer composition preferably comprises a blend of corn oil, canola oil, butter oil, arachidonic acid, and docosahexaenoic acid. This 15 blend of fats is believed to provide a fatty acid profile which is close to that of bitch milk and comprises from about 15 to 19% palmitic acid, from about 5 to 9% stearic acid, from about 34 to 38% oleic acid, from about 17 to 21% linoleic acid, from about 1 to 4% a-linolenic acid, from about 0.5 to 2% arachidonic acid, from about 0.2 to 1.0% docosahexaenoic acid (DHA), from about 2 to 5% Omega 3 fatty acids, from 20 about 18 to 22% Omega 6 fatty acids, and from about 1 to 4% trans fatty acids (expressed as a percentage of total fatty acids on a dry matter basis). The fatty acids preferably comprise about 25% to 35%, and most preferably, about 28% of the total composition on a dry matter basis. The composition also contains amounts of essential amino acids which exhibit 25 a profile similar to that of actual bitch milk. Expressed as a percentage of total essential amino acids on a dry matter basis, the amino acids preferably comprise from about 6 to 10% arginine, 4 to 8% histidine, 8 to 12% isoleucine, 16 to 20% leucine, from about 13 to 17% lysine, from about 2 to 7% methionine, from about 6 to 10% phenylalanine, from about 8 to 12% threonine, from about 1 to 4% tryptophan, WO 00/18247 PCTIUS99/20469 -8 from about 9 to 13% valine, from about 2 to 5% cystine, and from about 2 to 6% tyrosine. The essential amino acids preferably comprise about 15% to 25%, and most preferably, about 20% of the total composition on a dry matter basis. The composition also preferably contains, on a dry matter basis, from about 4 5 8% by weight lactose and from about 0.50% by weight fructooligosaccharide. Fructooligosaccharide (FOS) is preferably included in the formulation because studies have shown FOS to be beneficial to the intestinal health of many animals. FOS may be metabolized by beneficial intestinal bacterial species, such as Bifidobacterium. However, harmful intestinal bacteria, such as Salmonella, E. coli 10 and Clostridia are unable to process FOS. Therefore, FOS appear to promote a healthy intestinal environment in animals. The composition may also contain vitamins and minerals including, but not limited to Vitamin A acetate, cholecalciferol, d, I-alpha tocopheryl acetate, cyanocobalamin, riboflavin, niacinaminde, d-calcium pantothenate, folic acid, thiamin 15 mononitrate, pyridoxine hydrochloride, biotin, inositol, ascorbic acid, dextrose, tricalcium phosphate, potassium chloride, potassium citrate, magnesium sulfate, monosodium phosphate, zinc sulfate, copper sulfate, manganese sulfate, sodium selenite, potassium iodide, cobalt sulfate, and ferric methionine. In order that the invention may be more readily understood, reference is made 20 to the following examples which are intended to illustrate the invention, but not limit the scope thereof. Example 1 A milk substitute was prepared in accordance with the present invention by combining the following ingredients: WO 00/18247 PCT/US99/20469 -9 Formula A Ingredient Percentage Water 80.0 Na/Ca Caseinate 5.233 5 Whey Protein Concentrate 3.491 Maltodextrin 2.646 Butter Oil 2.412 Canola Oil 1.764 Mineral Premix' 1.147 10 Lactose 1.134 Corn Oil .869 Dried Egg Yolk .506 Emulsifier .200 Vitamin Premix 2 .128 15 Arachidonic Acid Supplement .100 Fructooligosaccharide .100 L-Histidine HCI .090 L-Arginine .060 Choline Chloride .055 20 DHA Supplement .040 Ascorbic Acid .025 'The "Mineral Premix" contained one or more of the following: tricalcium phosphate, potassium chloride, potassium citrate, magnesium sulfate, monosodium phosphate, 25 zinc sulfate, copper sulfate, manganese sulfate, sodium selenite, potassium iodide, cobalt sulfate, and ferric methionine. 2 The "Vitamin Premix" contained one or more of the following: Vitamin A acetate, cholecalciferol, d,l-alpha tocopheryl acetate, cyanocobalamin, riboflavin, niacinaminde, d-calcium pantothenate, folic acid, thiamin mononitrate, pyridoxine 30 hydrochloride, biotin, inositol, and ascorbic acid.
WO 00/18247 PCT/US99/20469 -10 To compare the formulation of the present invention with currently available products, an analysis of several commercially available bitch milk replacer formulas was conducted. The test formulas were JustBorn TM (JBD), available from Farnam Pet Products, Esbilac@ Milk Replacer for Puppies (ESB), available from Pet-Ag, Inc., 5 and Nurturall Puppy Balanced Milk Replacer (Nurtal), available from Veterinary Products Laboratory. Table 1 shows the protein, fat and carbohydrate content of those commercial formulas compared with the composition of the present invention (Formula A). Natural bitch milk was used as a baseline value (100)*. TABLE 1 10 Bitch ESB JBD Nurtal Formula A Protein 100 83.1 74.4 78.8 96.6 Fat 100 132.6 107 103.6 95 Carbohydrates 100 69.3 114.4 115.3 103.9 As can be seen from Table 1, and as shown in Fig. 1 which is a bar graph of 15 the data shown above, the composition of Formula A is much closer to natural bitch milk than the other products. The fatty acid and amino acid profiles of the commercially available products were also analyzed and compared with bitch milk and the composition of the present invention as shown below in Tables 2 and 3. The comparisons are expressed as a 20 percent of control (bitch=1 00%). The values for the amino acids and fatty acids are expressed as a percent of total protein and total lipids, respectively. *The milk fat values were obtained from Lonnerdal et al., "Developmental Changes in the Composition of Beagle Dog Milk", Am. J. Vet. Res., Vol. 42:662-666 (1981) and 25 Oftedal, "Lactation in the Dog: Milk Composition and Intake by Puppies", J. Nutr., 114:803-812 (1984).
WO 00/18247 PCT/US99/20469 -11 TABLE 2 - FATTY ACID PROFILE Control ESB JBD Nurtal Formula A Palmitic 100 44.4 58.4 53.9 70.8 Stearic 100 517.2 90.3 97.6 251.7 5 Oleic 100 78.1 73.4 71.8 97.7 Linoleic 100 77.2 309.7 337.9 133.1 Arachidonic 100 6.5 0 0 74.6 DHA 100 8.6 0 0 42.9 Trans Fatty Acids 100 577.9 17.6 0 62.9 10 TABLE 3 - AMINO ACID PROFILE Bitch ESB JBD Nurtal Formula A Arginine 100 84.6 71.5 95.4 79.3 Histidine 100 54 55.7 73.3 99.1 15 Isoleucine 100 106.7 99.8 107.7 108.1 Leucine 100 77.2 68 79.3 82 Lysine 100 92.1 146.6 145.9 140.9 Methionine 100 230.3 47 71.7 79 Cystine 100 63.8 41.5 53.6 111.6 20 Phenylalanine 100 105.4 112.3 135.2 118.5 Tryrosine 100 110.6 290.7 132.5 90.4 Threonine 100 120.3 78.8 93.2 123.7 Tryptophan 100 124.6 64.9 163.2 168.4 Valine 100 85.9 78.6 91.1 89.8 25 WO 00/18247 PCTIUS99/20469 -12 Figs. 2 and 3 are bar graphs illustrating the data from Tables 2 and 3, which clearly show that the fatty acid and amino acid profiles of the composition of the present invention is much more similar to the bitch milk profile than any of the other products. 5 Example 2 To study the effect of diet on serum fatty acid profile and amino acid profile, forty colony bred Beagle puppies from 7 litters were assigned to three treatments: bitch milk (CTL), (n=15) milk replacer I (MR-I) (n=14) comprising 40% protein and 30% fat (an example of the present invention), and milk replacer 11 (MR-l) (n=11) 10 comprising 33% protein and 40% fat (Esbilac@ Milk Replacer for Puppies from Pet Ag, Inc.). All puppies were allowed to nurse the dam for 24 hours with subsequent milk replacer feedings every 3 hours for days 1-2 and gradually increased to every 6 hours over the duration of the study. MR-I was found to contain higher levels of essential (EAA) and non-essential (NAA) amino acids than MR-Il. Puppies fed MR-1 15 were more similar to CTL in serum EAA and EAA:NAA ratio. These data indicate that the serum fatty acid profile and amino acid profile of growing puppies can be influenced by and are reflective of the milk replacer formulation. Example 3 To the determine the effect of milk composition on growth and body 20 composition of puppies, forty colony bred Beagle puppies from 7 litters were randomly assigned to three treatments: bitch milk (CTL) ( n=15), milk replacer I (MR-I from Example 2) (n=14), and milk replacer II (MR-Il from Example 2) (n-11). All puppies were allowed to nurse the dam for 24 hours. Milk replacer treatments were subsequently fed to the puppies every 3 hours and decreased to 4 feedings/day for 25 the remainder of the study (30 days). No differences were detected in intake between the MR puppies; however, puppies fed MR-1 had increased average daily weight gain and gain efficiency over MR-Il fed puppies, i.e., when the amount of product consumed was measured against the weight gained, MR- fed puppies had a WO 00/18247 PCT/US99/20469 -13 greater increase in body weight, indicating that the MR-I formulation is better at meeting the growth needs of puppies. The body composition of puppies fed MR-I did not differ from CTL puppies in body fat percentage, but was higher in lean tissue than both CTL and MR-Il. Puppies fed MR-Il were found to have the highest body fat and 5 lowest lean tissue. These data indicate that the MR-I formulation, which was more similar to bitch milk in fatty acid profile and amino acid profile, results in enhanced structural tissue growth indicating an improved nutritional status in neonatal puppies. While certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those skilled in the art that 10 various changes in the methods and apparatus disclosed herein may be made without departing from the scope of the invention, which is defined in the appended claims.
Claims (14)
1. An artificially produced canine milk substitute composition comprising, on a dry matter basis, from about 35 to 45% protein, from about 25 to 35% fat, and from about 10 to 25% carbohydrates. 5
2. The composition of claim 1 in which the source of protein comprises casein and whey in a weight ratio of about 70:30.
3. The composition of claim 1 comprising about 38% protein.
4. The composition of claim 1 comprising about 28% fat.
5. The composition of claim 1 comprising about 19% carbohydrates. 10
6. The composition of claim 1 in which the source of fat is selected from the group consisting of corn oil, canola oil, butter oil, arachidonic acid, docosahexaenoic acid, and blends thereof.
7. The composition of claim 1 containing fatty acids expressed as a percentage of total fatty acids on a dry matter basis, of from 15 to 19% palmitic acid, from about 5 15 to 9% stearic acid, from about 34 to 38% oleic acid, from about 17 to 21% linoleic acid, from about 1 to 4% a-linolenic acid, from about 0.5 to 2% arachidonic acid, from about 0.2 to 1 % docosahexaenoic acid (DHA), from about 2 to 5% Omega 3 fatty acids, from about 18 to 22% Omega 6 fatty acids, and from about 1 to 4% trans fatty acids. WO 00/18247 PCT/US99/20469 -15
8. The composition of claim 1 containing amino acids expressed as a percentage of total essential amino acids on a dry matter basis of from about 6 to 10% arginine, 4 to 8% histidine, 8 to 12% isoleucine, 16 to 20% leucine, from about 13 to 17% lysine, from about 2 to 7% methionine, from about 6 to 10% phenylalanine, from about 8 to 5 12% threonine, from about 1 to 4% tryptophan, from about 9 to 13% valine, from about 2 to 5% cystine, and from about 2 to 6% tyrosine.
9. The composition of claim 1 containing from about 4 to 8% by weight lactose.
10. The composition of claim 1 containing about 0.50% by weight fructooligosaccharide. 10
11. The composition of claim 1 containing from about 27 to 37% by weight fatty acids.
12. The composition of claim 1 containing from about 15 to 25% by weight essential amino acids.
13. The composition of claim 1 further comprising from about 4 to 8% by weight 15 lactose and about 0.50% by weight fructooligosaccharide.
14. A method for use in providing nutrition to a critical care canine, the method comprising: administering an amount of an artificially produced canine milk substitute composition comprising, on a dry matter basis, from about 35 to 45% protein, from 20 about 25 to 35% fat, and from about 10 to 25% carbohydrates to the canine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16377898A | 1998-09-30 | 1998-09-30 | |
US09/163778 | 1998-09-30 | ||
PCT/US1999/020469 WO2000018247A1 (en) | 1998-09-30 | 1999-09-07 | Canine milk substitute |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6028399A true AU6028399A (en) | 2000-04-17 |
AU753725B2 AU753725B2 (en) | 2002-10-24 |
Family
ID=22591529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU60283/99A Ceased AU753725B2 (en) | 1998-09-30 | 1999-09-07 | Canine milk substitute |
Country Status (8)
Country | Link |
---|---|
US (2) | US6245379B1 (en) |
EP (1) | EP1130974A1 (en) |
JP (1) | JP2002525087A (en) |
AU (1) | AU753725B2 (en) |
CA (1) | CA2346423C (en) |
NZ (1) | NZ509776A (en) |
RU (1) | RU2218812C2 (en) |
WO (1) | WO2000018247A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60318550T2 (en) * | 2002-02-04 | 2009-01-08 | Bristol-Myers Squibb Co. | BREAST MILK ADDITIONAL |
US20040044079A1 (en) * | 2002-09-04 | 2004-03-04 | The Iams Company | Methods and compositions for weight control |
US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
US7547450B2 (en) * | 2002-10-24 | 2009-06-16 | Nestec Ltd. | Senior feline food |
US8034372B2 (en) * | 2003-03-05 | 2011-10-11 | Nestec, Ltd. | Dietary supplement for athletic pets |
DK1641352T3 (en) * | 2003-07-07 | 2010-12-06 | Hills Pet Nutrition Inc | Compositions for improved oxidative status in cats |
US8633246B2 (en) * | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Omega-3 fatty acids for osteoarthritis |
US8633247B2 (en) * | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
US8921422B2 (en) * | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
US9040075B2 (en) * | 2003-12-19 | 2015-05-26 | Abbott Laboratories | Method of increasing lean body mass and reducing body fat mass in infants |
US20060002985A1 (en) * | 2004-07-02 | 2006-01-05 | Zicker Steven C | Compositions and methods for decreasing age-related deterioration in mental activities in companion animals |
EP1634599A1 (en) * | 2004-08-20 | 2006-03-15 | N.V. Nutricia | Iimmune stimulatory infant nutrition |
BRPI0516102A (en) * | 2004-10-14 | 2008-08-26 | Iams Company | schemes and methods adapted for young pets |
ES2579430T3 (en) * | 2004-12-30 | 2016-08-11 | Hill's Pet Nutrition, Inc. | Methods to increase the quality of life of a growing animal |
EP1830629A4 (en) * | 2004-12-30 | 2008-08-27 | Hills Pet Nutrition Inc | Methods for enhancing the quality of life of a senior animal |
PT2258219E (en) † | 2005-04-27 | 2014-08-25 | Nutricia Nv | Nutrition with lipids and non-digestible saccharides |
AU2008292864C1 (en) * | 2007-08-29 | 2015-03-05 | Mars, Incorporated | Single-serve cat food product and methods for same |
WO2009057994A1 (en) * | 2007-11-02 | 2009-05-07 | N.V. Nutricia | Unit dosage for brain health |
US20120178672A1 (en) * | 2009-03-18 | 2012-07-12 | Wolfe Robert R | Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis |
JP2013000041A (en) * | 2011-06-15 | 2013-01-07 | Kyodo Shiryo Kk | Substitute milk for calf for enhancing growth result of calf aged less than three months |
US9668500B2 (en) | 2012-04-24 | 2017-06-06 | Purina Animal Nutrition Llc | Feeding methods and systems for young livestock animals using sensory compounds |
US20140147548A1 (en) * | 2012-11-27 | 2014-05-29 | Purina Animal Nutrition Llc | Milk replacer products having adjusted fatty acid profiles and methods of feeding same |
DE102013103541A1 (en) * | 2013-04-09 | 2014-10-09 | Growth Finance Plus Ag | Liquid pet food for domestic cats or dogs and process for its preparation |
US11213051B2 (en) | 2014-07-02 | 2022-01-04 | Purina Animal Nutrition Llc | Milk replacer products containing halides and sources of hydrogen peroxide and methods of feeding same |
CN104187201A (en) * | 2014-09-26 | 2014-12-10 | 无锡东晟生物科技有限公司 | Nutritional feed for adult cat |
ITUA20161285A1 (en) * | 2016-02-19 | 2017-08-19 | Farm Procemsa S P A | COMPOSITION AND METHOD FOR OBTAINING EMULSIONS AND STABILIZABLE MICELLAR DISPERSIONS OF DEGREE OF DEGREE THROUGH THE USE OF MONO AND POLINSATURI FATTY ACIDS. |
US10940172B2 (en) | 2017-01-03 | 2021-03-09 | Purina Animal Nutrition Llc | Methods of feeding animals phytogenic products |
CN108308436A (en) * | 2018-01-30 | 2018-07-24 | 华兴宠物食品有限公司 | One bitches special health dog food and preparation method thereof |
US11058139B2 (en) * | 2018-07-03 | 2021-07-13 | Kerri Ann Langhorne | Recovery supplement for horses |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4351849A (en) * | 1966-05-26 | 1982-09-28 | Dec International | Foraminous mat products |
US4294856A (en) | 1977-01-04 | 1981-10-13 | Tokai Regional Fisheries Research Laboratory | Process for manufacture of artificial milk replacer for raising infant pigs and other infant animals |
DE2966967D1 (en) | 1978-08-25 | 1984-06-14 | Unilever Nv | Milk substitutes and process for preparing them |
DE3368377D1 (en) | 1982-04-16 | 1987-01-29 | Nestle Sa | Lipid composition for oral, enteral or parenteral feeding |
US4614653A (en) | 1983-07-26 | 1986-09-30 | Cargill, Incorporated | Milk replacer and method of feeding |
DE3629710A1 (en) * | 1986-09-01 | 1988-03-03 | Meyer Dorothee | SYNTHETIC MILK EXCHANGE FEED, IN PARTICULAR DOG MILK |
ES2007350A6 (en) | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
SE461498B (en) * | 1988-03-28 | 1990-02-26 | Jungvid Hans Ab | STARTING FEED TO BE ADMINISTERED TO YOUNG ANIMALS DURING THE FIRST WEEKS |
ES2033193B1 (en) | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | FAT MIXTURE FOR CHILD AND ADULT NUTRITION. |
US5294458A (en) | 1992-04-03 | 1994-03-15 | Maruha Corporation | Pet food |
US5221668A (en) | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
US5714161A (en) | 1993-04-22 | 1998-02-03 | Colgate Palmolive Company | Syringeable enteral diet for animals in a hypermetabolic state caused by the stress of medical and surgical illness |
US5635199A (en) | 1995-10-27 | 1997-06-03 | Nestec Ltd. | Support of pediatric patients |
US5733884A (en) | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5882714A (en) | 1996-04-15 | 1999-03-16 | The Iams Company | Queens milk replacer |
US5792501A (en) | 1996-04-15 | 1998-08-11 | The Iams Company | Queen's milk replacer |
DE69608801T2 (en) * | 1996-09-24 | 2000-10-12 | Nestle Sa | Milk replacement product and process for its manufacture |
-
1999
- 1999-07-28 US US09/362,401 patent/US6245379B1/en not_active Expired - Fee Related
- 1999-09-07 EP EP99969649A patent/EP1130974A1/en not_active Withdrawn
- 1999-09-07 JP JP2000571773A patent/JP2002525087A/en active Pending
- 1999-09-07 NZ NZ509776A patent/NZ509776A/en not_active Application Discontinuation
- 1999-09-07 AU AU60283/99A patent/AU753725B2/en not_active Ceased
- 1999-09-07 CA CA002346423A patent/CA2346423C/en not_active Expired - Fee Related
- 1999-09-07 RU RU2001104337/13A patent/RU2218812C2/en not_active IP Right Cessation
- 1999-09-07 WO PCT/US1999/020469 patent/WO2000018247A1/en not_active Application Discontinuation
-
2001
- 2001-04-09 US US09/829,168 patent/US7404976B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2218812C2 (en) | 2003-12-20 |
AU753725B2 (en) | 2002-10-24 |
EP1130974A1 (en) | 2001-09-12 |
US6245379B1 (en) | 2001-06-12 |
US20020018828A1 (en) | 2002-02-14 |
CA2346423A1 (en) | 2000-04-06 |
WO2000018247A1 (en) | 2000-04-06 |
JP2002525087A (en) | 2002-08-13 |
CA2346423C (en) | 2005-08-09 |
NZ509776A (en) | 2003-07-25 |
US7404976B2 (en) | 2008-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU753725B2 (en) | Canine milk substitute | |
Jurgens | Animal feeding and nutrition | |
McDowell | Vitamins in animal and human nutrition | |
Rooke et al. | Feeding tuna oil to the sow at different times during pregnancy has different effects on piglet long-chain polyunsaturated fatty acid composition at birth and subsequent growth | |
Luisa | Animal life-cycle feeding and nutrition | |
JP2000512154A (en) | How to enhance docosahexaenoic acid in milking dairy cows | |
CA2274291C (en) | Carnitine-supplemented diets for gestating and lactating swine | |
JP2012152220A (en) | Method for preventing hyperthyroidism in cat and composition comprising limited selenium and iodine | |
Molik et al. | The effect of the photoperiod and exogenous melatonin on the protein content in sheep milk | |
Cunningham et al. | The effect of fat-free diets on lambs and goats | |
Burns et al. | Assessment of the quantity of biologically available phosphorus in yeast RNA and single-cell protein | |
Devilat et al. | Dietary amino acid balance in growing-finishing pigs: effect on diet preference and performance | |
Attia et al. | Soy lecithin in diets for rabbit does improves productive and reproductive performance | |
Weiss et al. | Are your cows getting the vitamin they need | |
KR101669291B1 (en) | Compositions and methods for increasing iron absorption | |
MXPA01002440A (en) | Canine milk substitute | |
Radkowska et al. | Concentration of bioactive components in the milk of Simmental cows depending on the feeding system | |
Partridge et al. | A note on the response of growing pigs to supplemental biotin | |
RU2751961C1 (en) | Method for increasing the digestibility of nutritional components of feed when including ultrafine chromium oxide particles in diet of cattle | |
Chiou et al. | Ewe milk replacer diets for young lambs. I. Effect of age of lamb and dietary fat on digestibility of the diet, nitrogen retention and plasma constituents | |
Walker et al. | The utilization by preruminant lambs of isolated soya bean protein in low protein milk replacers | |
RU2537555C2 (en) | Dry full ration fodder for large breed dogs balanced in terms of amino acid composition with proved bio-functional properties (versions) | |
Lotfollahzadeh et al. | Effect of Parenteral Administration of Vitamin A in Dairy Cattle During Dry Period, on Vitamin A Status of Neonatal Calves | |
CN113796466A (en) | Hair beautifying cream for dogs as well as preparation method and application thereof | |
El-Gendy et al. | Supplemental Rumen Protected Methionine and/or Choline for Zaraibi Goats: 2-Productive Performance of Kids Suckled Dam Colostrum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |